Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Share-based Compensation (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Share-based Compensation for 13 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 23.1% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Dec 2025, down 13.64% year-over-year, with the annual reading at $18.5 million for FY2025, 13.64% down from the prior year.
  • Share-based Compensation for Q4 2025 was $4.5 million at Theravance Biopharma, down from $4.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $16.9 million in Q4 2021, with the low at $4.5 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $8.4 million, with a median of $6.3 million recorded in 2023.
  • The sharpest move saw Share-based Compensation increased 8.79% in 2021, then crashed 58.92% in 2022.
  • Over 5 years, Share-based Compensation stood at $16.9 million in 2021, then plummeted by 58.92% to $7.0 million in 2022, then decreased by 16.2% to $5.8 million in 2023, then increased by 0.03% to $5.8 million in 2024, then dropped by 23.1% to $4.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $4.5 million, $4.6 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.